Edition:
United States

Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

2.87USD
21 Jul 2017
Change (% chg)

$0.07 (+2.50%)
Prev Close
$2.80
Open
$3.20
Day's High
$3.22
Day's Low
$2.65
Volume
17,690,993
Avg. Vol
1,763,452
52-wk High
$5.59
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​
Thursday, 20 Jul 2017 05:00pm EDT 

July 20 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO.Aeterna Zentaris Inc - ‍Strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​.David A. Dodd has ceased to be company's president and CEO with immediate effect..Board of directors of company has appointed Michael Ward as company's chief executive officer.Aeterna Zentaris Inc - ‍Formed a special committee to consider and evaluate various strategic and financing alternatives available to company​.Aeterna Zentaris Inc - ‍Special committee to evaluate alternatives including considering and recommending changes to co's management and governance​.  Full Article

Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults
Friday, 30 Jun 2017 09:15am EDT 

June 30 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults.Aeterna Zentaris - "Believe FDA review period of NDA will be up to 6 months, setting stage for potential approval of product late in 2017, early in 2018".Aeterna Zentaris Inc - Focus is to be prepared to launch Macrilen in Q1 of 2018.  Full Article

Aeterna Zentaris qtrly loss per share $0.31
Monday, 8 May 2017 04:30pm EDT 

May 8 (Reuters) - Aeterna Zentaris Inc ::Aeterna Zentaris reports first quarter 2017 financial and operating results.Aeterna Zentaris Inc - qtrly revenue $261,000 versus $242,000; qtrly loss per share $0.31.Aeterna Zentaris Inc - do not anticipate conducting clinical trials of zoptrex with respect to any other indications.Aeterna Zentaris Inc - co's focus has now shifted entirely to filing new drug application for macrilen.  Full Article

Aeterna Zentaris says ZoptEC Phase 3 clinical study of Zoptrex did not achieve primary endpoint
Monday, 1 May 2017 08:00am EDT 

May 1 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint.Aeterna Zentaris Inc - company expects to submit Macrilen NDA in Q3 of 2017.Aeterna Zentaris Inc - Zoptrex generally performed no better than comparator drug with respect to secondary efficacy endpoints.Aeterna Zentaris - median overall survival period for patients treated with Zoptrex was 10.9 months which is not a statistically significant.Aeterna Zentaris - intention to submit Macrilen NDA in Q3 of 2017 and, if product receives FDA approval, to commercially launch product in Q1 of 2018.  Full Article

Aeterna Zentaris files for common shares stock shelf offering of up to $50 mln
Tuesday, 21 Mar 2017 04:49pm EDT 

Aeterna Zentaris Inc :Aeterna Zentaris Inc- files for common shares stock shelf offering of up to $50 million - sec filing.  Full Article

Aeterna Zentaris qtrly loss per share $0.71
Wednesday, 15 Mar 2017 04:48pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports fourth quarter and full-year 2016 financial and operating results .Aeterna Zentaris Inc - qtrly loss per share $0.71.  Full Article

Aeterna Zentaris announces EMA pediatric committee agreement
Tuesday, 7 Mar 2017 08:30am EST 

Aeterna Zentaris Inc : Aeterna Zentaris announces EMA pediatric committee agreement on the pediatric investigation plan for macrilen(TM) . Aeterna Zentaris Inc- .Aeterna Zentaris - pediatric committee of EMA agreed co may defer conducting pip until after it files a MAA seeking authorization for use of Macrilen.  Full Article

Aeterna Zentaris completes Zoptrex(tm) pivotal Phase 3 clinical trial in advanced endometrial cancer
Monday, 30 Jan 2017 05:30pm EST 

Aeterna Zentaris Inc : Aeterna Zentaris announces completion of Zoptrex(TM) pivotal Phase 3 clinical trial in advanced endometrial cancer; expects to report top-line results in April 2017 . Aeterna Zentaris Inc - Currently expects to lock clinical database and to report top-line results in April 2017 for Phase 3 zoptec with zoptrex .Aeterna Zentaris Inc - Occurrence of 384th death in pivotal phase 3 zoptec study with zoptrex.  Full Article

Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen
Wednesday, 26 Oct 2016 08:00am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris completes patient recruitment for confirmatory phase 3 trial of Macrilen .Aeterna Zentaris - expects to file a new drug application for Macrilen with United States food and drug administration during first half of 2017.  Full Article

Aeterna and Specialised Therapeutics Asia sign exclusive license agreement
Wednesday, 12 Oct 2016 08:00am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive license agreement for the potential marketing of Zoptrex(TM) in Australia and New Zealand . Aeterna Zentaris Inc - company expects to complete phase 3 clinical trial for Zoptrex in 2016 . Aeterna Zentaris Inc - plans to submit a new drug application for Zoptrex(TM) to United States Food And Drug Administration (FDA) in first half of 2017 . Aeterna Zentaris - co to be entitled to receive non-refundable upfront payment in consideration for license to sta of co's IP related to Zoptrex(TM) . Aeterna Zentaris - entitled to non-refundable upfront payment in consideration allso for grant to STA of right to commercialize Zoptrex in territory . Aeterna Zentaris - STA has also agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones . Aeterna zentaris- STA has also agreed to make additional payments to co such as double-digit royalties on future net sales of Zoptrex(TM) in territory . Aeterna Zentaris - STA will be responsible for development, reimbursement, commercialization of product in territory (Australia, New Zealand) .Aeterna Zentaris Inc - supply agreement with STA pursuant to which company will supply zoptrex(TM) to sta for duration of license agreement.  Full Article